Alembic Pharma Receives Four Observations From U.S. FDA For Panelav Facility

Earlier on Monday, U.S. health regulator has conducted an inspection at it Panelav facility in Gujarat and issued Form 483 with four procedural observations according to Alembic Pharmaceuticals.

“The U.S. Food and Drug Administration has conducted an inspection at Alembic Pharmaceuticals general oral solid formulation facility located at Panelav from 9-13 March, 2020,” the drug firm said in a filing to the exchanges.
This was a scheduled inspection, and at the end of the inspection, the U.S. FDA issued a Form 483 with four procedural observations.
No particular observation is related to the data integrity or repetitive in nature.

“The company will provide comprehensive corrective action report to address each observation. The company is committed to maintaining highest quality standards that meet U.S. FDA standards,” it said.
The U.S. health regulator issues observations by means of a FDA Form 483 notifying the company’s management of objectionable conditions at the facility inspected.

Related Posts

Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

India’s largest drugmaker, Sun Pharmaceutical Industries Ltd., announced on Wednesday that its European biotech partner Philogen has voluntarily withdrawn the marketing authorisation application (MAA) for its investigational therapy Nidlegy from…

Govt supports indigenous manufacturing of complex pharma excipients by Nitika Pharmaceutical Specialties

For commercial-scale production of 14 complex excipients The Technology Development Board (TDB), Department of Science and Technology (DST), Government of India has extended financial support to Nitika Pharmaceutical Specialties Private…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Sun Pharma ropes in Richard Ascroft as North America CEO

Sun Pharma ropes in Richard Ascroft as North America CEO

Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen

Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen

Most Advanced Cancer Care is New Chapter @ Sir Ganga Ram

Most Advanced Cancer Care is New Chapter @ Sir Ganga Ram